Doliprane 500mg Paracetamol

Brand History and Evolution

Doliprane is one of France's most iconic and widely recognized pharmaceutical brands, primarily known for its paracetamol-based formulation used to treat pain and fever. Originally developed by the French pharmaceutical company Bottu in the mid-20th century, it has become a staple in French medicine cabinets. Its legacy is deeply rooted in the French healthcare system, where it remains the leading analgesic by volume.

Manufacturing and Local Integration

The production of Doliprane is a matter of national industrial pride in France. It is primarily manufactured at dedicated facilities in Lisieux and Compiègne, France. This localized production strategy ensures a stable supply chain for the French market and supports the local economy through significant industrial infrastructure and employment.

Ownership and Global Context

Today, Doliprane is managed by Opella, the consumer healthcare division of the French global pharmaceutical giant Sanofi. While Sanofi has historically owned and operated the brand, as of 2024 and looking toward 2025-2026, Sanofi has been in negotiations for a potential sale of a controlling stake in Opella to private equity firms like CD&R. However, the brand remains headquarted in France, and the French government has been actively involved in ensuring that both production and headquarters remain on French soil to guarantee health sovereignty.